

Updated: 06/2025 DMMA Approved: 06/2025

Request for Prior Authorization for Xiaflex (collagenase clostridium histolyticum) Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Xiaflex (collagenase clostridium histolyticum) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Xiaflex (collagenase clostridium histolyticum)Prior Authorization Criteria:

Coverage may be provided with a <u>diagnosis</u> of **Dupuytren's Contracture** and the following criteria is met:

- Member must be 18 years of age or older
- Documentation the member has one of the following:
 - o a finger flexion contracture with a palpable cord of at least one finger (other than the thumb)
 - o a positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top
- Documentation that the flexion deformity results in functional limitations
- Documentation of which cords on which hand are being treated and dates of treatment
- A maximum of two cords in the same hand may be treated during a single treatment visit (all treatment visits must be at least 4 weeks apart)
- A cord may not be injected more than 3 times and at an interval less than 4 weeks
- Must not have received a surgical treatment (e.g. fasciectomy, fasciotomy) on the selected primary joint within 90 days before the first injection
- **Duration of Approval:** 4 months

Coverage may be provided with a <u>diagnosis</u> of **Peyronie's disease** and the following criteria is met:

- Member must be 18 years of age or older
- Must be prescribed by or in consultation with a urologist
- Documentation the member has stable disease defined as symptoms that have remained unchanged for at least 3 months
- Documentation of a palpable plaque and curvature deformity of at least 30 degrees and less than 90 degrees at the start of therapy
- Erectile function must be intact
- Injections for Peyronie's disease are limited to 4 treatment cycles. (Each cycle consists of 2 Xiaflex injections and one remodeling procedure.)
- Exclusion criteria:
 - o sexual or erectile dysfunction associated with Peyronie's disease



Updated: 06/2025 DMMA Approved: 06/2025

• **Duration of Approval:** 6 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



Updated: 06/2025 DMMA Approved: 06/2025

XIAFLEX (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative.

PHONE: (844) 325-6253 Monday	through Friday 8:00am to 7:00pm	
PROVIDER IN		
Requesting Provider:	NPI:	
Provider Specialty:	Office Contact:	
Office Address:	Office Phone:	
	Office Fax:	
MEMBER INF		
Member Name:	DOB:	
Member ID:	Member weight: Height:	
REQUESTED DRUG		
Medication:	Strength:	
Directions:	Quantity: Refills	
Is the member currently receiving requested medication?		
No		
Is this medication being used for a chronic or long-term cond	ition for which the medication may be necessary for the life	
of the patient? Yes No		
Billing Inf	ormation	
This medication will be billed: at a pharmacy OR	<u> </u>	
medically (if medically pl	ease provide a JCODE:	
	ember's home Other	
Place of Servic		
Name:	NPI:	
Address:	Phone:	
MEDICAL HISTORY (Co	omplete for ALL requests)	
Diagnosis: Dupuytren's Contracture Peyronie's D		
Please select all of the following that apply (please attach sup	pporting documentation:	
	a palpable cord of at least one finger (other than the thumb)	
a positive "table top test" defined as the inability	to simultaneously place the affected finger(s) and palm flat	
against a table top	Y	
3		
the flexion deformity is causing functional limitat	ions	
Which cord(s) are being treated?		
Which cord(s) are being treated?		
Was the cord previously treated? Yes No	-	
If yes when?		
If yes when?		



Updated: 06/2025 DMMA Approved: 06/2025

Member Name: Member ID:			
		ted primary joint 90 days	or less before the date of the first
For Peyronie's Disease:			
Does the member have a palpable Yes No	e plaque and curvature de	formity of at least 30 deg	rees and less than 90 degrees?
Does the member have stable dis <i>for at least 3 months)?</i> Yes		nentation the member's s	ymptoms have remained unchanged
Is erectile function intact? \(\sum \) Ye	es 🗌 No		
	CURRENT		
Madigation Nama	CURRENT or PR	REVIOUS THERAPY	Status (Discontinued &
Medication Name	CURRENT or PR Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)
Medication Name			`
Medication Name			`
Medication Name			`
		Dates of Therapy	Why/Current)
	Strength/ Frequency	Dates of Therapy	Why/Current)
	Strength/ Frequency	Dates of Therapy	Why/Current)
	Strength/ Frequency ORTING INFORMATI	Dates of Therapy	Why/Current)